Handa Pharmaceuticals (ROCO:6620) Beneish M-Score: 0.00 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6620 Handa Pharmaceuticals Inc ROCO:6620
75 GF Score
Price NT$84.70
GF Value NT$183.93
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Handa Pharmaceuticals Beneish M-Score?

Handa Pharmaceuticals ROCO:6620 -1.28% 75 Beneish M-Score is 0.00 as of Jul. 22, 2026. GuruFocus rates ROCO:6620 with a GF Score™ of 75/100 and a GF Value™ of NT$183.93 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 910 Drug Manufacturers companies, Handa Pharmaceuticals ranks worse than 109890% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Handa Pharmaceuticals's Beneish M-Score or its related term are showing as below:

During the past 12 years, the highest Beneish M-Score of Handa Pharmaceuticals was 2.32. The lowest was -1.68. And the median was 0.32.


Handa Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Handa Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Handa Pharmaceuticals Beneish M-Score Chart

Handa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 2.32 -1.68 0.00

Handa Pharmaceuticals Quarterly Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.41 -1.68 0.79 0.10 0.00

ROCO:6620 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Handa Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Handa Pharmaceuticals Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Handa Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Handa Pharmaceuticals's Beneish M-Score falls into.


ROCO:6620
75GF Score
Handa Pharmaceuticals Inc ROCO:6620
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Handa Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Handa Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Sep24) TTM:
Total Receivables was NT$586.0 Mil.
Revenue was 299.92 + 489.533 + 0 + 188.099 = NT$977.6 Mil.
Gross Profit was 262.162 + 384.205 + 0 + 187.871 = NT$834.2 Mil.
Total Current Assets was NT$4,312.3 Mil.
Total Assets was NT$5,892.5 Mil.
Property, Plant and Equipment(Net PPE) was NT$84.9 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$83.5 Mil.
Selling, General, & Admin. Expense(SGA) was NT$114.6 Mil.
Total Current Liabilities was NT$117.8 Mil.
Long-Term Debt & Capital Lease Obligation was NT$37.4 Mil.
Net Income was 172.897 + 209.458 + 0 + 106.286 = NT$488.6 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0.0 Mil.
Cash Flow from Operations was 152.84 + 19.062 + 0 + 103.471 = NT$275.4 Mil.
Total Receivables was NT$0.0 Mil.
Revenue was 209.67 + 215.533 + 217.372 + 300.033 = NT$942.6 Mil.
Gross Profit was 209.325 + 215.243 + 217.063 + 299.689 = NT$941.3 Mil.
Total Current Assets was NT$0.0 Mil.
Total Assets was NT$0.0 Mil.
Property, Plant and Equipment(Net PPE) was NT$0.0 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$10.4 Mil.
Selling, General, & Admin. Expense(SGA) was NT$166.9 Mil.
Total Current Liabilities was NT$0.0 Mil.
Long-Term Debt & Capital Lease Obligation was NT$0.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(585.998 / 977.552) / (0 / 942.608)
=0.599455 / 0
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(941.32 / 942.608) / (834.238 / 977.552)
=0.998634 / 0.853395
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4312.266 + 84.856) / 5892.512) / (1 - (0 + 0) / 0)
=0.253778 /
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=977.552 / 942.608
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(10.362 / (10.362 + 0)) / (83.451 / (83.451 + 84.856))
=1 / 0.495826
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(114.613 / 977.552) / (166.933 / 942.608)
=0.117245 / 0.177097
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((37.414 + 117.838) / 5892.512) / ((0 + 0) / 0)
=0.026347 /
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(488.641 - 0 - 275.373) / 5892.512
=0.036193

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
Handa Pharmaceuticals (ROCO:6620) has a Beneish M-Score of 0.00 as of Jul. 22, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Handa Pharmaceuticals and its competitors. According to the industry distribution chart, Handa Pharmaceuticals ranks #999999 out of 910 companies in the Drug Manufacturers industry.
Is Handa Pharmaceuticals' Beneish M-Score too high?
Handa Pharmaceuticals' current Beneish M-Score is 0.00. Based on the distribution chart, Handa Pharmaceuticals ranks #999999 out of 910 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Handa Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Handa Pharmaceuticals' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Handa Pharmaceuticals ranks #999999 out of 910 companies for Beneish M-Score. This places Handa Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Handa Pharmaceuticals and its competitors. Handa Pharmaceuticals's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Handa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Handa Pharmaceuticals (ROCO:6620) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$183.93, compared to a current price of NT$84.70 — trading 53.9% below its estimated fair value. The current Beneish M-Score is 0.00. Handa Pharmaceuticals' overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Handa Pharmaceuticals (ROCO:6620), the current Beneish M-Score is 0.00 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Handa Pharmaceuticals (ROCO:6620) Overvalued in 2026?

Based on GuruFocus' analysis, Handa Pharmaceuticals stock appears to be undervalued. The current stock price of NT$84.70 is trading 53.9% below its estimated GF Value™ of NT$183.93. GuruFocus considers Handa Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ROCO:6620:

  • Beneish M-Score: 0.00
  • GF Value™: NT$183.93 vs. price of NT$84.70 (53.9% below fair value)
  • GF Score™: 75/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6620 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Handa Pharmaceuticals Business Description

Address Nanke 3rd Road, 3F-1,3F-2, No.23, Xinshi Dist, Tainan, TWN, 74147
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.
75GF Score

Get the complete analysis for ROCO:6620

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$84.70
Price
NT$183.93
GF Value